Trial Profile
A Randomized, Placebo-Controlled, Double-Blind, Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel (Nab-Paclitaxel, Abraxane®) With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 20 Feb 2024
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary) ; Mifepristone
- Indications Advanced breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- 06 Jun 2023 Primary endpoint (Progression-free survival (PFS)) has not been met, according to Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 06 Jun 2023 Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 14 Mar 2022 Status changed from recruiting to active, no longer recruiting.